Cellectar Biosciences Inc (CLRB) concluded trading on Wednesday at a closing price of $0.43, with 14.58 million shares of worth about $6.27 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.29% during that period and on June 11, 2025 the price saw a gain of about 16.64%. Currently the company’s common shares owned by public are about 46.08M shares, out of which, 45.31M shares are available for trading.
Stock saw a price change of -7.56% in past 5 days and over the past one month there was a price change of 61.61%. Year-to-date (YTD), CLRB shares are showing a performance of 42.74% which decreased to -87.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $3.42 during that period. The average intraday trading volume for Cellectar Biosciences Inc shares is 11.64 million. The stock is currently trading 43.59% above its 20-day simple moving average (SMA20), while that difference is up 50.19% for SMA50 and it goes to -53.99% lower than SMA200.
Cellectar Biosciences Inc (NASDAQ: CLRB) currently have 46.08M outstanding shares and institutions hold larger chunk of about 11.42% of that.
The stock has a current market capitalization of $19.67M and its 3Y-monthly beta is at 0.55. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 2.47 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLRB, volatility over the week remained 11.48% while standing at 12.97% over the month.
Stock’s fiscal year EPS is expected to rise by 55.21% while it is estimated to increase by 0.80% in next year. EPS is likely to shrink at an annualized rate of 24.38% for next 5-years, compared to annual growth of 40.27% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on December 05, 2024 offering a Buy rating for the stock and assigned a target price of $13 to it. Stock get a Buy rating from Ladenburg Thalmann on December 21, 2016.
